Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06)

Fig. 3

Forrest plots showing the survival outcomes of patient subgroups. (A) Progression-free survival (PFS) and (B) Overall survival (OS). (HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; PS, performance status; GEJ, gastroesophageal junction; NLR, neutrophil to lymphocyte ratio)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us